<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286308</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003841</org_study_id>
    <nct_id>NCT04286308</nct_id>
  </id_info>
  <brief_title>Cortical-Basal Ganglia Speech Networks</brief_title>
  <official_title>Cortical-Basal Ganglia Speech Networks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study the researchers want to learn more about brain activity related to
      speech perception and production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Speech production is disrupted in a number of neurological diseases that involve the basal
      ganglia, including Parkinson's disease (PD) and dystonia. The investigators will use a novel
      experimental approach and combination of analytic techniques to elucidate the contribution of
      neural activity in cortical-basal ganglia circuits to the hierarchical control of speech
      production, in subjects undergoing deep brain stimulation surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects providing the interpretable speech related electrophysiological data collection.</measure>
    <time_frame>Duration of single DBS surgery</time_frame>
    <description>The number of subjects providing the interpretable speech related electrophysiological data during DBS surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Essential Tremor</condition>
  <condition>Dystonia</condition>
  <arm_group>
    <arm_group_label>Brain signal data collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brain signal data collection at the time of deep brain stimulation (DBS) surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electrophysiological data collection</intervention_name>
    <description>Electrophysiological data collection at the time of DBS surgery.</description>
    <arm_group_label>Brain signal data collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects scheduled for DBS implantation, as determined by the clinical
             multidisciplinary movement disorders board with definitive diagnosis of Parkinson's
             disease, essential tremor or dystonia.

          2. Subjects able to provide informed consent and comply with task instructions.

          3. Subjects 18-85 years old

        Exclusion Criteria:

          1. Subjects with reported hearing loss.

          2. Non-English-speaking subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Richardson, MD, PhD</last_name>
    <phone>412-877-4386</phone>
    <email>mark.richardson@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Lerman, MS</last_name>
    <phone>617-724-7759</phone>
    <email>lerman.irene@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert M Richardson, MD PhD</last_name>
      <phone>412-877-4386</phone>
      <email>mark.richardson@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Irene Lerman, MS</last_name>
      <phone>6177247947</phone>
      <email>lerman.irene@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Robert Mark Richardson</investigator_full_name>
    <investigator_title>Director of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

